Investor Presentation Q1 2018
Investor Presentation
First three months of 2018
Slide 56
TresibaⓇ sets a new standard for basal insulin initiation by
lowering the risk of hypoglycaemia
TresibaⓇ is a leap on the innovation ladder by
further reducing nocturnal hypoglycaemia
50%
53%
reduction in nocturnal reduction in nocturnal
hypoglycaemia¹
hypoglycaemia²
TresibaⓇ has consistently demonstrated
relevant reductions in severe hypoglycaemia
Patients Study
Hazard ratio
[95% CI]
1.12 [0.68; 1.86]
BEGIN
New-generation
insulin
T1D
0.65 [0.48; 0.89]*
SWITCH 1
Modern
insulin
Human
insulin
IGlar U100
T2D
SWITCH 2
InsulatardⓇ
Half life: 25 hours
Variability: Low
Half life: 12-19 hours
Variability: Medium
0.74 [0.61; 0.90]*
TresibaⓇ
BEGIN
0.81 [0.42; 1.56]
0.54 [0.21; 1.42]
0.49 [0.26; 0.94]*
DEVOTE
0.60 [0.48; 0.76]*
Half life: 5-10 hours
Variability: High
Maintenance period
Full treatment period
0.125 0.25 0.5 1
2
Favours Tresiba® Favours comparator
1 P. D. Home, A. Fritsche, S. Schinzel & M. Massi-Benedetti, Diabetes, Obesity and Metabolism 12: 772-
779, 2010
2 DEVOTE, American Diabetes Association 77th Scientific Sessions, 3-CT-SY22, June 12 2017
IGlar U100: Insulin glargine U100
* Statistically significant difference
Note: Phase 3a BEGIN: Severe-third-party assistance; Phase 3b SWITCH: severe-third-party assistance and
adjudicated; Phase 3b DEVOTE: severe-third-party assistance.
T1D: Type 1 diabetes; T2D: Type 2 diabetes; CI: Confidence interval
Source: Ratner et al. Diabetes Obes Metab 2013; Lane et al. Diabetologia 2016;59; Wysham et al.
Diabetologia 2016; DEVOTE, American Diabetes Association 77th Scientific Sessions, 3-CT-SY22, June 12 2017View entire presentation